Abstract: | Being able to carry zidovudine (AZT) at known concentrations into CD4+/CD38+ and CD14+ cells permits: | - to reduce the drug dosage and to increase the interval for administration (until 1 dose I.V. every week); | | - to modulate the drug concentration into the CD4+/CD38 an CD14+ cells in relation to the in vitro determined HIV sensitiveness; | | - to eliminate haematological, medullary and general toxicity; | | - to be able to treat severely hill patients. | Further studies are necessary in order to: | - To find out the better phase to start the therapy; | | - To use several drugs with different mechanisms of action in order to slow down as much as possible the presence of resistant viral strains. | | - As for other drugs which are beginning to be used with artificial vehicles, futher studies are required to improve the selectivity and safety of LIPOAZT for the target cells including macrophages. |
|